FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124828691> ?p ?o ?g. }

• W2124828691 endingPage "204" @default.
• W2124828691 startingPage "197" @default.
• W2124828691 abstract "The purpose of this study is to determine the presence of disseminated tumor cells in bone marrow or apheresis product, and also to evaluate the clinical significance of contaminated products and the efficacy of CD34(+) selection and high-dose chemotherapy in patients with Stage III breast cancer. Fifty-five patients were enrolled in this prospective cohort study. Whereas CD34(+) positive selection was not carried out in the first group (unselected group, n:31), CD34(+) positive selection was performed in the second group (CD34 selected group, n:24). Tumor cells were detected with anticytokeratin monoclonal antibody in the bone marrow, apheresis product and positive fraction. Tumor cells were found in six (19.3%) patients in unselected group and four patients (16.6%) in CD34 selected group (P = 0.76). The percentages of distant metastases were found higher in unselected group (51.6% vs. 25%, P < 0.01). Although there were no differences between the two groups for disease free survival (DFS; 44% vs. 74%, P = 0.24) or overall survival (54% vs. 68%, P = 0.84), DFS was significantly lower in patients with tumor cells than in patients without tumor cells (21% vs. 62%, P = 0.02). In conclusion, the presence of tumor cells in bone marrow or apheresis product decreases DFS in patients with Stage III breast cancer who underwent high-dose chemotherapy. CD34(+) selection does not change survivals, but it may decrease the distant metastases." @default.
• W2124828691 created "2016-06-24" @default.
• W2124828691 creator A5000743644 @default.
• W2124828691 creator A5002550962 @default.
• W2124828691 creator A5009854348 @default.
• W2124828691 creator A5019056226 @default.
• W2124828691 creator A5028254375 @default.
• W2124828691 creator A5043984651 @default.
• W2124828691 creator A5045615729 @default.
• W2124828691 creator A5068225726 @default.
• W2124828691 creator A5071341532 @default.
• W2124828691 creator A5073962611 @default.
• W2124828691 creator A5070087899 @default.
• W2124828691 date "2009-01-01" @default.
• W2124828691 modified "2023-10-14" @default.
• W2124828691 title "The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34⁺selection and high-dose chemotherapy in patients with Stage III breast cancer" @default.
• W2124828691 cites W125031896 @default.
• W2124828691 cites W1980143004 @default.
• W2124828691 cites W1980299983 @default.
• W2124828691 cites W1982583218 @default.
• W2124828691 cites W2023636722 @default.
• W2124828691 cites W2037547770 @default.
• W2124828691 cites W2064419741 @default.
• W2124828691 cites W2068503417 @default.
• W2124828691 cites W2088040588 @default.
• W2124828691 cites W2089915420 @default.
• W2124828691 cites W2095259408 @default.
• W2124828691 cites W2102734247 @default.
• W2124828691 cites W2115548460 @default.
• W2124828691 cites W2128237030 @default.
• W2124828691 cites W2130231521 @default.
• W2124828691 cites W2132308320 @default.
• W2124828691 cites W2137093959 @default.
• W2124828691 cites W2141696951 @default.
• W2124828691 cites W2150449240 @default.
• W2124828691 cites W2162992800 @default.
• W2124828691 cites W2224437187 @default.
• W2124828691 cites W2242711566 @default.
• W2124828691 cites W2271721498 @default.
• W2124828691 cites W2316646839 @default.
• W2124828691 cites W2321753125 @default.
• W2124828691 cites W23839722 @default.
• W2124828691 cites W90738772 @default.
• W2124828691 doi "https://doi.org/10.1002/jca.20211" @default.
• W2124828691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19816961" @default.
• W2124828691 hasPublicationYear "2009" @default.
• W2124828691 type Work @default.
• W2124828691 sameAs 2124828691 @default.
• W2124828691 citedByCount "2" @default.
• W2124828691 countsByYear W21248286912015 @default.
• W2124828691 crossrefType "journal-article" @default.
• W2124828691 hasAuthorship W2124828691A5000743644 @default.
• W2124828691 hasAuthorship W2124828691A5002550962 @default.
• W2124828691 hasAuthorship W2124828691A5009854348 @default.
• W2124828691 hasAuthorship W2124828691A5019056226 @default.
• W2124828691 hasAuthorship W2124828691A5028254375 @default.
• W2124828691 hasAuthorship W2124828691A5043984651 @default.
• W2124828691 hasAuthorship W2124828691A5045615729 @default.
• W2124828691 hasAuthorship W2124828691A5068225726 @default.
• W2124828691 hasAuthorship W2124828691A5070087899 @default.
• W2124828691 hasAuthorship W2124828691A5071341532 @default.
• W2124828691 hasAuthorship W2124828691A5073962611 @default.
• W2124828691 hasBestOaLocation W21248286911 @default.
• W2124828691 hasConcept C10205521 @default.
• W2124828691 hasConcept C121608353 @default.
• W2124828691 hasConcept C126322002 @default.
• W2124828691 hasConcept C126894567 @default.
• W2124828691 hasConcept C143998085 @default.
• W2124828691 hasConcept C146357865 @default.
• W2124828691 hasConcept C151730666 @default.
• W2124828691 hasConcept C2776694085 @default.
• W2124828691 hasConcept C2776738589 @default.
• W2124828691 hasConcept C2780007613 @default.
• W2124828691 hasConcept C28328180 @default.
• W2124828691 hasConcept C530470458 @default.
• W2124828691 hasConcept C54355233 @default.
• W2124828691 hasConcept C71924100 @default.
• W2124828691 hasConcept C86803240 @default.
• W2124828691 hasConcept C89560881 @default.
• W2124828691 hasConcept C90924648 @default.
• W2124828691 hasConceptScore W2124828691C10205521 @default.
• W2124828691 hasConceptScore W2124828691C121608353 @default.
• W2124828691 hasConceptScore W2124828691C126322002 @default.
• W2124828691 hasConceptScore W2124828691C126894567 @default.
• W2124828691 hasConceptScore W2124828691C143998085 @default.
• W2124828691 hasConceptScore W2124828691C146357865 @default.
• W2124828691 hasConceptScore W2124828691C151730666 @default.
• W2124828691 hasConceptScore W2124828691C2776694085 @default.
• W2124828691 hasConceptScore W2124828691C2776738589 @default.
• W2124828691 hasConceptScore W2124828691C2780007613 @default.
• W2124828691 hasConceptScore W2124828691C28328180 @default.
• W2124828691 hasConceptScore W2124828691C530470458 @default.
• W2124828691 hasConceptScore W2124828691C54355233 @default.
• W2124828691 hasConceptScore W2124828691C71924100 @default.
• W2124828691 hasConceptScore W2124828691C86803240 @default.
• W2124828691 hasConceptScore W2124828691C89560881 @default.
• W2124828691 hasConceptScore W2124828691C90924648 @default.
• W2124828691 hasIssue "5" @default.

• next